Caris Life Sciences released interim results from the Achieve 1 validation study showing its Caris Detect multicancer early detection (MCED) assay delivered stage‑dependent sensitivity and high specificity across a mixed diagnostic and screening population. Sensitivity rose with stage: ~57% for stage I, ~70% for stage II and 99% for stage IV, with overall specificity near 95% in undiagnosed participants. Caris reported the assay met performance expectations in enriched cohorts and noted a blinded validation cohort is pending. The company said it plans a commercial launch in the second quarter contingent on completion of validation and regulatory checks. Investors and diagnostic competitors will watch the blinded validation readout closely; strong, prospective MCED performance often dictates payer acceptance and clinical adoption pathways.